Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain
Authors:
- 1 October 2011
- journal article
- clinical trial
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 23 (5-6) , 328-332
Abstract
Background and aims: Several publications and guidelines stress the efficacy and safety of opioid-based therapy for cancer and non-cancer pain management. The first point of the World Health Organization (WHO) guidelines recommends that, if possible, analgesics should be given by mouth. This advice fully matches the European Society for Medical Oncology (ESMO) guidelines, which advise that opioids should be titrated to take effect as rapidly as possible. The European Association for Palliative Care (EAPC) guidelines specify that transdermal fentanyl should be administered only in patients with stable analgesic requirements. The aim of this study was to assess the efficacy and influence on the quality of life of controlled-release (CR) oxycodone in patients who had obtained no or only partial pain relief after transdermal (TTD)-based opioid therapy. Methods: Forty-one consecutive patients experiencing persistent cancer and non-cancer related pain and in treatment with transdermal-based opioid therapy for at least 5 days were enrolled in this open-label, multicenter observational study. All patients were switched from transdermal to oral opioid therapy with oxycodone CR for 21 days. Pain intensity was rated on a numeric rating scale (NRS) from 0 to 10 (0=no pain, 10=maximum severity). Patients were asked to rate their perceptions on efficacy and pain interference on the quality of life on an NRS from 0 to 10 (0=no interference, 10=maximum interference). Results: After 3 days with oxycodone CR, pain intensity decreased by 38.83% (ppppConclusions: Switching from transdermal opioid to oxycodone CR treatment is effective and leads to patients’ improved satisfaction and quality of life.Keywords
This publication has 26 references indexed in Scilit:
- Controlled-Release Oxycodone and Pregabalin in the Treatment of Neuropathic Pain: Results of a Multicenter Italian StudyEuropean Neurology, 2008
- Oxycodone: a review of its use in the management of painCurrent Medical Research and Opinion, 2007
- Efficacy and tolerability of once-daily OROS® hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: Results of a 6-week, randomized, open-label, noninferiority analysisClinical Therapeutics, 2007
- Differential effect of opioids in patients with chronic pancreatitis: An experimental pain studyScandinavian Journal of Gastroenterology, 2007
- ESMO Minimum Clinical Recommendations for the management of cancer painAnnals of Oncology, 2005
- The Role of Opioids in Cancer Pain ManagementPain Practice, 2005
- Opioid Therapy for Chronic PainNew England Journal of Medicine, 2003
- Characterization and validation of a pharmacokinetic model for controlled‐release oxycodoneBritish Journal of Clinical Pharmacology, 1996
- Pharmacologic Treatment of Cancer PainNew England Journal of Medicine, 1996
- New Clinical-Practice Guidelines for the Management of Pain in Patients with CancerNew England Journal of Medicine, 1994